Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 2Sarcoma, Kaposi 1Sarcoma 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Neurofibromatosis 1 1Neoplasm Metastasis 1Liposarcoma 1Leiomyosarcoma 1Glioma 1Colorectal Neoplasms 1Brain Neoplasms 1Acquired Immunodeficiency Syndrome 1

Interventions

Doxorubicin 4Specimen Handling 3Radiotherapy 3Biopsy 3pazopanib 2Temozolomide 2Sorafenib 2Radiation 2Magnetic Resonance Spectroscopy 2Ifosfamide 2talimogene laherparepvec 1saracatinib 1sapanisertib 1rubitecan 1romidepsin 1peposertib 1liposomal doxorubicin 1cixutumumab 1abemaciclib 1Thalidomide 1Nivolumab 1Molecular Diagnostic Techniques 1Microarray Analysis 1MLN 8237 1Ipilimumab 1HhAntag691 1Gemcitabine 1Etoposide 1Docetaxel 1Diathermy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leiomyosarcoma × abemaciclib × Clear all
NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
74 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡